

ASX RELEASE

Volpara Half Year Results and Investor Webinar Notification

Wellington, NZ, 13 November 2023: <u>Volpara Health Technologies</u> ("Volpara," "the Group," or "the Company"; ASX: VHT), a global leader in software for the early detection and prevention of breast cancer, will be hosting an investor webinar on **Tuesday 21**st **November** at 9:00am AEDT (Sydney/Melbourne), 11:00am NZDT (Auckland/Wellington) to update shareholders on its H1 FY24 financial results.

The call will be hosted by Teri Thomas, CEO and Managing Director and Craig Hadfield, Chief Financial Officer.

Webinar details

Date: Tuesday 21st November 2023

Time: 9:00am AEDT (Sydney/Melbourne), 11:00am NZDT (Auckland/Wellington)

To register: https://us02web.zoom.us/webinar/register/WN XUifVss8QPS3kDGrOvHDog

Dial in details: Will be provided to you upon registration

Participants will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen or can submit them in advance to hhowlett@we-worldwide.com.

Authorisation & Additional Information

This announcement was authorised by the Chief Executive Officer and Managing Director of Volpara Health Technologies Limited.

ENDS

For further information, please contact:

Corporate Enquiries	investor Relations	Media Enquiries
Teri Thomas, CEO & MD	Hannah Howlett	Trevor Chappell
Volpara Health Technologies	WE Communications	WE Communications
Teri.thomas@volparahealth.com	hhowlett@we-worldwide.com	tchappell@we-worldwide.com
t: +64 4 499 6029	t: +61 4 5064 8064	t: +61 4 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

Volpara Health Technologies makes software to save families from cancer. We help leading healthcare providers positively impact communities around the word. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain quality, and guide recommendations about additional imaging, genetic testing, and other interventions.

Our focus on customer value means that our Al-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, our software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, Volpara has raised A\$132 million. Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit www.volparahealth.com